Received notice of the subsidy grant decision related to the AMED public offering project. Project period: 2026\/9\/14 to 2027\/3\/31. Estimated grant amount for fiscal year 2026 is 79,993 thousand yen; final amount will be confirmed by AMED’s notification. No impact on consolidated results for the fiscal year ending March 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4978","jir_company_name":"Reprocell, Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-17","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4978-20260917-01.pdf","jir_short_summary":"Received notice of the subsidy grant decision related to the AMED public offering project. Project period: 2026\/9\/14 to 2027\/3\/31. Estimated grant amount for fiscal year 2026 is 79,993 thousand yen; final amount will be confirmed by AMED's notification. No impact on consolidated results for the fiscal year ending March 2027.","jir_summary":"### Performance \/ Subsidy Overview\nThis notice informs that the proposal related to the AMED public offering project has been selected and the grant decision notice has been received. The public offering project period is from September 14, 2026 to March 31, 2027, and the estimated grant amount for fiscal year 2026 is 79,993 thousand yen. The final grant amount and the timing of recognition will be determined by AMED's final notification.\n\n### Impact and Financial Outlook Going Forward\nOfficial grant amount confirmation is expected next year, and will be announced promptly once determined. It is explicitly stated that there is no expected impact on the consolidated results for the fiscal year ending March 2027. While research and development funding is expected to strengthen the research framework, the direct financial impact on earnings is considered limited.","jir_financial_highlights":"Public offering project period: September 14, 2026 to March 31, 2027 (Unknown)\nFiscal year 2026 grant amount (estimated): 79,993 thousand yen (Unknown)","jir_category":"","jir_hashtags":"#Reprocell, #PublicOfferingProject, #R&DFunding, #Subsidy","jir_key_figures":"Public offering project period: September 14, 2026 to March 31, 2027\nFiscal year 2026 grant amount (estimated): 79,993 thousand yen\nFinal grant amount confirmation by AMED final notification","jir_meta_title":"\u3010Reprocell\u3011AMED Subsidy Grant Decision Notice\uff5cSeptember 2026","jir_meta_description":"Reprocell has received a subsidy grant decision for the AMED public offering project. Period: 2026\/9\/14-2027\/3\/31. Fiscal year 2026 grant amount is 79,993 thousand yen (estimated); final will be confirmed by AMED notification. No impact on 2027 period.","jir_og_title":"Reprocell AMED Subsidy Grant Decision Notice","jir_og_description":"Receipt of subsidy grant decision for AMED public offering project. Project period from 2026\/9\/14 to 2027\/3\/31. Final amount awaiting confirmation, no impact on the 2027 fiscal year.","jir_og_image_url":"\/assets\/og\/company-corporate_restructuring.jpg","jir_chart_data_collection":"[]","ir_related_company":58459,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-114820","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n